ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $4.14 Consensus Price Target from Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have earned a consensus recommendation of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $4.14.

A number of brokerages recently issued reports on ALXO. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Friday, January 24th. Stifel Nicolaus lowered their target price on shares of ALX Oncology from $3.00 to $1.50 and set a “hold” rating for the company in a report on Friday, March 7th. Jefferies Financial Group upgraded ALX Oncology from a “hold” rating to a “buy” rating and upped their price target for the stock from $2.00 to $3.00 in a research note on Thursday, March 6th. Piper Sandler lifted their price objective on ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, March 6th. Finally, UBS Group dropped their target price on ALX Oncology from $4.00 to $2.20 and set a “buy” rating on the stock in a report on Monday, January 27th.

ALX Oncology Stock Performance

Shares of ALX Oncology stock opened at $0.96 on Friday. ALX Oncology has a 12 month low of $0.89 and a 12 month high of $17.83. The firm has a market capitalization of $50.60 million, a P/E ratio of -0.32 and a beta of 1.01. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The business has a fifty day simple moving average of $1.34 and a two-hundred day simple moving average of $1.58.

Hedge Funds Weigh In On ALX Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP increased its holdings in shares of ALX Oncology by 6.7% in the 4th quarter. Two Sigma Investments LP now owns 704,131 shares of the company’s stock worth $1,176,000 after purchasing an additional 44,072 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of ALX Oncology by 64.6% during the fourth quarter. Two Sigma Advisers LP now owns 823,900 shares of the company’s stock valued at $1,376,000 after buying an additional 323,400 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in ALX Oncology by 55.6% in the 4th quarter. Nuveen Asset Management LLC now owns 164,790 shares of the company’s stock worth $275,000 after buying an additional 58,896 shares in the last quarter. Deutsche Bank AG raised its position in ALX Oncology by 521.0% in the 4th quarter. Deutsche Bank AG now owns 101,113 shares of the company’s stock worth $169,000 after buying an additional 84,830 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new position in ALX Oncology during the 4th quarter valued at about $125,000. 97.97% of the stock is owned by institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.